Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
ID:
Password:
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

Agents/Distributors
 Regional Subscription Agents/Distributors
 
Current Topics in Biochemical Research   Volumes    Volume 4 
Abstract
GnRH-based chimeric proteins: future targeting therapy for adenocarcinomas?
Ahmi Ben-Yehudah, Haya Lorberboum-Galski
Pages: 49 - 59
Number of pages: 11
Current Topics in Biochemical Research
Volume 4 

Copyright © 2001 Research Trends. All rights reserved

ABSTRACT

As the number of cancer-related deaths has not decreased in recent years, major efforts are being made to find new drugs for cancer treatment. In the past few years many chimeric proteins have been developed to target and kill cancer cells. This class of targeting molecules, designed and constructed by gene fusion techniques, comprises both the cell targeting and the cell killing moieties.

Luteinizing hormone releasing hormone (LHRH), also termed gonadotropin-releasing hormone (GnRH), accounts for the hypothalamic-pituitary gonadal control of human reproduction. The involvement of GnRH has been demonstrated in several carcinomas of hormone-responsive tissues. Exploiting this common feature, we constructed and highly purified Pseudomonas exotoxin (PE)-based chimeric toxins (GnRH-PE), with an eye to targeting those cancer cells bearing GnRH binding sites. In eukaryotic cells, PE enzymaticaly inactivates EF-2 (Elongation Factor-2), thereby arresting protein synthesis and causing cell death. We found that a surprisingly wide variety of cancers, all confined to the adenocarcinoma type, are killed by the GnRH-PE chimeric proteins. We also demonstrated that these chimeric proteins efficiently inhibit cancer growth of well-established colon adenocarcinomas in nude mice.

Because of the immunogenicity and the non-specific toxicity of bacterial toxins such as PE, we have now developed new chimeric proteins, introducing apoptosis-inducing proteins as novel killing components. GnRH-apoptosis-inducing chimeric proteins efficiently inhibited the cell growth of adenocarcinoma cell lines and eventually led to cell death.

The major findings of our studies are the surprisingly widespread presence of GnRH binding sites in human neoplasms-in most of the adenocarcinomas we tested, and the impressive ability of our new GnRH-based chimeric proteins to target and kill such cancer cells both in vitro and in vivo. Therefore, GnRH-based chimeric proteins are the most promising targeting reagents for treatment of human adenocarcinomas.

Buy this Article


 
search


E-Commerce
Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Login
Search Products
Browse in Alphabetical Order : Journals
Series/Books
Browse by Subject Classification : Journals
Series/Books

Miscellaneous
Ordering Information Ordering Information
Downloadable forms Downloadable Forms